WS #15869
The FDA has authorized the first wearable device for continuous ketone and blood sugar monitoring and approved Rasonque (daraxonrasib), a first-in-class targeted therapy for metastatic pancreatic cancer. These approvals signal a continued acceleration in regulatory pathways for innovative treatments, providing a tailwind for biotech firms with strong pipelines and reducing regulatory uncertainty for novel drug developers.
Biotech Regulatory Breakthrough
The FDA has authorized the first wearable device for continuous ketone and blood sugar monitoring and approved Rasonque (daraxonrasib), a first-in-class targeted therapy for metastatic pancreatic cancer. These approvals signal a continued acceleration in regulatory pathways for innovative treatments, providing a tailwind for biotech firms with strong pipelines and reducing regulatory uncertainty for novel drug developers.